About 122 results
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Journal of the American College of Cardiology;

Mar 16th, 2019 - Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and mortality globally (S1- 1–S1-3). In the United States, it is also the leading cause of death for people of most racial/ethnic groups, with an estimated cost of >$200 billion annually in healthcare services, medications,...

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Feb 1st, 2019 - Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages.

Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events
Zheng, S. et. al.

Jan 21st, 2019 - Question: What is the association of aspirin use with cardiovascular events and bleeding events in individuals without cardiovascular disease? Findings: In this meta-analysis of 13 trials with 164 225 participants without cardiovascular disease, aspirin use was associated with a lower risk of cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal st...

Evidence of CV benefits of Mediterranean diet growing

Jan 5th, 2019 - After the holidays, often as part of a New Year’s resolution, it is common for people to think about changing to a healthier diet. One option is the Mediterranean diet, which was recently named by U.S. News & World Report as the top overall diet, the best diet for healthy eating, the best plant-based diet, the best diet for diabetes and the easiest diet to follow. Much evidence emerged in 2018 ...

Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019

Dec 17th, 2018 - Atherosclerotic cardiovascular disease (ASCVD)—defined as coronary heart disease, cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin—is the leading cause of morbidity and mortality for individuals with diabetes and results in an estimated $37.3 billion in cardiovascular-related spending per year associated with diabetes (1). Common conditions coexis...

Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019

Dec 17th, 2018 - Chronic kidney disease (CKD) is diagnosed by the persistent presence of elevated urinary albumin excretion (albuminuria), low estimated glomerular filtration rate (eGFR), or other manifestations of kidney damage (1,2). In this section, the focus will be on CKD attributed to diabetes (diabetic kidney disease), which occurs in 20–40% of patients with diabetes (1,3–5). CKD typically develops after...

New Vascepa Approval Opens Up Treatment to Millions

Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascular disease (CVD). The drug, thus, could well be used by millions of patients in the United States alone. The high-dose, purified eicosapentaenoic acid ...

Icosapent ethyl approved for cardiovascular risk reduction
Catherine Hackett

Dec 13th, 2019 - Icosapent ethyl (Vascepa) has gained an indication from the Food and Drug Administration for reduction of cardiovascular events in patients with high triglycerides who are at high risk for cardiovascular events. Olivier Le Moal/Getty Images It is “the first FDA-approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin.

FDA Approves Amarin's Vascepa for Cardiovascular Risk Reduction

Dec 12th, 2019 - The Food and Drug Administration (FDA) has approved icosapent ethyl (Vascepa, Amarin) to reduce the risk for cardiovascular (CV) events in people with elevated triglyceride levels and either established CV disease or diabetes with other CV risk factors, the agency announced today. The indication applies to use of the purified, high-dose marine-oil preparation as an add-on option for patients on...

Starting Statin in Childhood Protects FH Hearts

Oct 16th, 2019 - Statin use started in childhood for familial hypercholesterolemia (FH) kept atherosclerotic plaque levels normal and was associated with better outcomes in adulthood, long-term follow-up of a clinical trial cohort showed. Mean progression of carotid intima-media thickness was similar for these patients as for their siblings without FH (0.0056 vs 0.0057 mm per year) and remained nonsignificantly...

Older patients who stop statins may be increasing their cardiovascular risk
Steve Cimino

Aug 2nd, 2019 - Discontinuing statins was associated with an increased risk of hospital admission for a cardiovascular event, according to a study of elderly French patients with no history of heart disease. RogerAshford/Thinkstock “The results of this study suggest potential cardiovascular risk reduction associated with continuing statin therapy after the age of 75 years in persons already taking these drugs.

ACC Pathway Empowers Cardiologists to Use Diabetes Drugs for Heart Disease

Jul 23rd, 2019 - This transcript has been edited for clarity. Today I'm going to discuss the American College of Cardiology (ACC) Expert Consensus Decision Pathway[1] on novel therapies—the SGLT2 inhibitors and GLP-1 receptor agonists—for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease. I joke that this is about cardiologists who finally want to be endoc...

VADT at 15 Years Published: Lack of 'Legacy Effect' in Diabetes

Jun 4th, 2019 - The lack of a "legacy effect" of intensive glucose lowering at 15 years in the Veterans Affairs Diabetes Trial (VADT) suggests that other cardiovascular risk reduction strategies should be prioritized in patients with advanced type 2 diabetes and established cardiovascular disease. That is the conclusion of Kasia J. Lipska, MD, Yale School of Medicine, New Haven, Connecticut, and Neda Laiteerap...

FDA grants Priority Review to Vascepa for cardiovascular risk reduction
Lucas Franki

May 30th, 2019 - The Food and Drug Administration has granted a Priority Review to the supplemental new drug application for icosapent ethyl (Vascepa). Wikimedia Commons/FitzColinGerald/Creative Commons License If approved, Vascepa – which is produced by Amarin – would be the first drug indicated to reduce residual cardiovascular risk in patients with LDL cholesterol managed by statins who still have persistent.

Genetic Validation for New LDL Cholesterol-Lowering Target

Mar 31st, 2019 - A new study confirms the mechanism by which ATP citrate lyase inhibition lowers plasma low-density-lipoprotein cholesterol (LDL-C) levels and provides genetic validation for this as a target for cardiovascular risk reduction. The study indicates that ATP citrate lyase inhibitors lower LDL-C by the same mechanism of action as statins, and genetic variants associated with lower plasma LDL-C in th...

AHA: Consider obesity as CVD risk factor in children
Jeff Craven

Feb 25th, 2019 - The American Heart Association has included obesity and severe obesity in its updated scientific statement outlining risk factors and considerations for cardiovascular risk reduction in high-risk pediatric patients. The scientific statement is an update to a 2006 American Heart Association (AHA) statement, adding details about obesity as an at-risk condition and severe obesity as a moderate-ris.

For 2019, ADA and ACC Align Their Diabetes Recommendations

Dec 17th, 2018 - For the first time in its annual diabetes management guidelines, the American Diabetes Association (ADA) has aligned its recommendations with those of the American College of Cardiology (ACC) for cardiovascular risk reduction in people with type 2 diabetes.    The 2019 Standards of Medical Care in Diabetes, published online December 17 in Diabetes Care (and updated in real-time) also incorporat...

FDA Rejects Canakinumab in CVD Prevention

Oct 19th, 2018 - It's official: the FDA declined to approve canakinumab (Ilaris) for cardiovascular risk reduction on the strength of data from the CANTOS trial, according to drugmaker Novartis. "Based on the correspondence, the CANTOS data would not support labeling for the use of canakinumab as a targeted therapy for those patients with cardiovascular disease who achieved a reduction of hsCRP [high-sensitivit...

The State of the Art in Cardiovascular Risk Reduction

Mar 4th, 2018 - The increasing burden of cardiovascular disease (CVD), along with rising costs, is driving a renewed focus on CVD risk reduction. More and more, prevention and population health are in the spotlight in scientific meetings and journals. This high-value, high-return approach to addressing CVD has the potential to prevent at least 200,000 deaths from heart disease and stroke each year in the Unite...

AHA: Meditation May Play a Role in Lowering CVD Risk

Sep 28th, 2017 - Mediation may benefit cardiovascular risk, but traditional care for risk factors such as high cholesterol and blood pressure remains the mainstay of preventing heart disease, according to a scientific statement from the American Heart Association (AHA). A systematic review of approximately 400 studies found a possible, though not conclusive, benefit of meditation on cardiovascular risk reductio...